Frazier Life Sciences Management L.P. boosted its position in Immatics (NASDAQ:IMTX - Free Report) by 17.5% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,354,711 shares of the company's stock after purchasing an additional 202,255 shares during the quarter. Frazier Life Sciences Management L.P. owned about 1.13% of Immatics worth $15,457,000 at the end of the most recent reporting period.
Several other hedge funds have also recently added to or reduced their stakes in IMTX. HighVista Strategies LLC purchased a new stake in Immatics in the 2nd quarter valued at $904,000. abrdn plc purchased a new stake in Immatics in the 3rd quarter valued at $2,657,000. Vestal Point Capital LP grew its holdings in Immatics by 36.4% in the 3rd quarter. Vestal Point Capital LP now owns 3,750,000 shares of the company's stock valued at $42,788,000 after buying an additional 1,000,000 shares in the last quarter. Perceptive Advisors LLC grew its holdings in Immatics by 76.5% in the 2nd quarter. Perceptive Advisors LLC now owns 8,086,159 shares of the company's stock valued at $93,961,000 after buying an additional 3,503,750 shares in the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new stake in Immatics in the 2nd quarter valued at $2,404,000. 64.41% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
IMTX has been the subject of a number of research analyst reports. Piper Sandler initiated coverage on Immatics in a report on Monday, October 7th. They set an "overweight" rating and a $19.00 price target for the company. Cantor Fitzgerald reiterated an "overweight" rating on shares of Immatics in a report on Thursday, September 5th. The Goldman Sachs Group upgraded Immatics to a "strong-buy" rating in a report on Monday, November 25th. Finally, Bank of America lowered their price target on Immatics from $16.00 to $15.00 and set a "buy" rating for the company in a report on Tuesday, November 19th. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $16.67.
Check Out Our Latest Research Report on Immatics
Immatics Trading Down 3.0 %
Immatics stock traded down $0.23 during midday trading on Tuesday, reaching $7.55. 401,128 shares of the stock traded hands, compared to its average volume of 498,220. The company has a 50-day simple moving average of $9.02 and a two-hundred day simple moving average of $10.93. Immatics has a 12-month low of $7.46 and a 12-month high of $13.77. The firm has a market cap of $901.14 million, a PE ratio of -11.52 and a beta of 0.74.
About Immatics
(
Free Report)
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
Read More
Before you consider Immatics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immatics wasn't on the list.
While Immatics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
